Rapid Reviews in Hematology™: Updates from San Diego on Therapeutic Advancements in Hemolytic Anemias – A Focus on Paroxysmal Nocturnal Hemoglobinuria

Release Date: February 18, 2021
Expiration Date: February 18, 2022

Activity Overview

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired blood disorder characterized by hemolytic anemia, thrombosis, and impaired bone marrow function. Given its spectrum of disease, PNH is associated with significant disease burden. Importantly, there have been ongoing advances related to current and emerging therapeutic options for its management that offer significant promise.

This online, on-demand virtual symposium features a panel discussion among hematology experts, highlighting the implications and applications of data regarding the treatment and management of PNH. The panel discusses topics that include the efficacy and safety of available and investigational therapies, strategies for treatment planning, and quality of life aspects for affected patients.

This educational activity is an archive of the live virtual symposium held on January 28, 2021.
 

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Apellis Pharmaceuticals, Inc.
 

Target Audience

These activities are intended for hematologists, oncologists, and other health care professionals interested in understanding the treatment guidelines and strategies for managing patients with hemolytic anemias. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals are also invited to attend.
 

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Relate the pathophysiology of PNH to targets for its management
• Examine emerging clinical trial evidence regarding current and emerging therapies for patients with PNH
• Develop patient-centric treatment plans for patients with PNH
   

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities.

Faculty

Craig M. Kessler, MD, MACP
Professor of Medicine and Pathology
Director, Division of Coagulation
Lombardi Comprehensive Cancer Center
Georgetown University Medical Center
Washington, DC

Disclosures:Grant/Research Support: Octapharma, Takeda Pharmaceutical Company; Consultant: CSL Behring, Octapharma, Takeda Pharmaceutical Company; Other Support: Director, 340B Program at Hemophilia Treatment Centers, Novartis Pharmaceuticals, Rigel Pharmaceuticals.

Robert A. Brodsky, MD
The Johns Hopkins Family Professor of Medicine and Oncology
Director, Division of Hematology
Director, Physician-Scientist Pathway Osler Medical Program
Johns Hopkins University School of Medicine
Baltimore, MD

Disclosures:Disclosures: Consultant: Alexion Pharmaceuticals.

Catherine Broome, MD
Associate Professor of Medicine
Georgetown University
Lombardi Comprehensive Cancer Center
Washington, DC

Disclosures:Consultant: Alexion Pharmaceuticals, Apellis Pharmaceuticals, Argenx, Sanofi.

Ilene Ceil Weitz, MD
Professor of Clinical Medicine
Jane Anne Nohl Division of Hematology
Keck School of Medicine
University of Southern California
Los Angeles, CA

Disclosures:Consultant: Alexion Pharmaceuticals, Apellis Pharmaceuticals; Speakers’ Bureau: Alexion Pharmaceuticals, Apellis Pharmaceuticals.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.